首页良性前列腺增生治疗及预后证据详情

Transurethral bipolar plasmakinetic prostatectomy for benign prostatic hyperplasia in high-risk and senior patients in China: a systematic review and meta-analysis

原文:2019年 发布于 Zhonghua Yi Xue Za Zhi 99卷 第10期 778-782 浏览量:1527次 原文链接

作者: Zhang Z. Y. Zhao M. J. Hong B. A. Ma L. L. Jin Y. H. Zeng X. T. Gong K.

作者单位: Department of Urology, the First Hospital of Peking University, Beijing 100034, China. Department of Cardiology, the Fist Affiliated Hospital of Henan University, Kaifeng 475004, China. Department of Cardiology, the Fist Affiliated Hospital of Henan Chinese Medicine University, Zhengzhou 450046, China. Department of Urology, Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071.

归属分类: 良性前列腺增生治疗及预后证据

DOI: 10.3760/cma.j.issn.0376-2491.2019.10.015

关键词: *Bipolar Disorder China Humans Male Prostatectomy *Prostatic Hyperplasia Quality of Life *Transurethral Resection of Prostate Treatment Outcome Benign prostatic hyperplasia High-risk and senior patients Meta-analysis Systematic review Transurethral bipolar plasmakinetic prostatectomy

文献简介

Objective: To evaluate the effectiveness and safety of transurethral bipolar plasmakinetic prostatectomy in the treatment of benign prostatic hyperplasia in high-risk and senior patients in China. Methods: The PubMed, Cochrane Library, CBM, CNKI and WanFang databases were searched with computer for collecting relevant interventional case series from establishment dates to September 14, 2018. After quality evaluation and data extraction independently conducted by two authors, the Meta-analysis was performed using the Comprehensive Meta-analysis V2 software. Results: Eighteen studies involving 1 899 patients are included. Maximum flow rate increased to 12.28 ml/s (95%CI: 8.42-16.14), 12.88 ml/s (95%CI: 9.85-15.92) ,14.32 ml/s (95%CI: 10.47-18.18), 14.93 ml/s (95%CI: 10.19-19.67) and 20.00 ml/s (95%CI: 19.08-20.92) in 1, 3, 6, 12 and 24 months after surgery, respectively. International prostate symptom score decreased to -18.60 (95%CI: -23.20--14.00), -17.62 (95%CI: -20.21--15.03), -19.14 (95%CI: -20.70--17.59), -19.06 (95%CI: -21.53--16.60) and -22.90 (95%CI: -24.26--21.54), respectively. Quality of life decreased to -2.38 (95%CI: -4.26--0.50), -3.39 (95%CI: -4.57--2.21),-3.75 (95%CI: -4.14--3.36), -3.36(95%CI: -4.56--2.16), and -4.58(95%CI: -4.75--4.41). Post void residual decreased to -231.16 ml (95%CI: -288.30--174.01), -76.10 ml (95%CI: -116.71--35.50), -159.90 ml(95%CI: -207.21--112.59) and -87.70 ml (95%CI: -91.91--83.48). The event rate of postoperative adverse reactions all were not high. Conclusion: Transurethral bipolar plasmakinetic prostatectomy has better clinical efficacy and no obvious side effects in the treatment of benign prostatic hyperplasia in high-risk and senior patients in China.

热门文献